Autoimmune Lymphoproliferative Syndrome Differential Diagnoses
- Author: Luke M Webb, MD; Chief Editor: Harumi Jyonouchi, MD more...
With its classic presenting clinical triad of generalized lymphadenopathy, splenomegaly, and cytopenias in childhood, autoimmune lymphoproliferative syndrome (ALPS) can present a significant diagnostic challenge for clinicians. Because ALPS is rare and has clinical and laboratory features that can overlap those of other common pediatric hematologic disorders (eg, sporadic acute idiopathic thrombocytopenic purpura [ITP]), clinicians must first rule out other, more immediate life-threatening conditions (eg, leukemia and lymphoma).
ALPS has distinguishing laboratory features that should be sought during evaluation (see Workup) to help differentiate this condition from other clinically similar conditions and thereby help keep the patient from undergoing unnecessary diagnostic and therapeutic interventions. Its rarity notwithstanding, ALPS should be considered in the differential diagnosis of any child who presents with chronic nonmalignant lymphadenopathy and splenomegaly, particularly when a family history of a similar disease is elicited.
Establishing a specific diagnosis is important for prognosis and treatment. In the past, patients not uncommonly experienced a delayed diagnosis or misdiagnosis that led to unnecessary surgical procedures (including repeated lymph nodes biopsies and unwarranted splenectomy) or even courses of chemotherapy.
In addition to the conditions listed in the differential diagnosis, other problems to be considered include the following:
Hyper IgM (HIGM) syndrome
Interleukin (IL)–2 receptor alpha-chain deficiency
Lymphoma (Hodgkin and non-Hodgkin)
X-lined lymphoproliferative syndrome (XLP)
Issues of misdiagnosis (often with malignancy or chronic infection) and obtaining informed consent for therapies like bone marrow transplantation (leading to wrongful death litigation) constitute the major medicolegal pitfalls in the management of ALPS. Accordingly, the participation of experienced specialists is essential to the diagnosis and treatment of patients with this syndrome. These patients require a treatment team with a pediatric hematologist as team leader and case manager.
Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome (IPEX)
Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967 Jun. 70(6):891-9. [Medline].
Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995 Jun 16. 81(6):935-46. [Medline].
John MJ, Rajasekhar R, Mathews V. Autoimmune lymphoproliferative syndrome (ALPS): a rare cause of immune cytopenia. Indian Pediatr. 2008 Feb. 45(2):148-50. [Medline].
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992 Mar 26. 356(6367):314-7. [Medline].
Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992 Aug. 90(2):334-41. [Medline]. [Full Text].
Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004 Sep 30. 351(14):1409-18. [Medline].
Rao VK, Straus SE. Autoimmune Lymphoproliferative Syndrome. Young NS, Gerson SL, High KA. Clinical Hematology. 2006. Chapter 58.
Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007 May 22. 104(21):8953-8. [Medline].
Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010 Oct 7. 116(14):e35-40. [Medline]. [Full Text].
Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology. 2006 Feb. 11(1):15-23. [Medline].
Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer A. Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol. 2008 Jul 1. 181(1):440-8. [Medline].
Fleisher TA. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis. Immunol Res. 2008. 40(1):87-92. [Medline].
Oliveira JB, Fleisher TA. Autoimmune Lymphoproliferative Syndrome. Curr Opin All Clin Immunol. 2004. 4:497-503.
Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician. 1998 Oct 15. 58(6):1313-20. [Medline].
Blessing J, Johnson J, Zhang K. Gene Reviews: Autoimmune Lymphoproliferative Syndrome. Gene Reviews. Available at http://www.ncbi.nlm.nih.gov/books/NBK1108/. Accessed: June 15, 2009.
Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol. 2006 Feb. 81(2):81-5. [Medline].
Rao VK, Dowdell KC, Dale JK, Dugan F, Pesnicak L, Bi LL. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol. 2007 Dec. 82(12):1049-55. [Medline].
Turbyville J, Mikita C, Mudra K. Asplenia. Medscape Reference. Available at http://emedicine.medscape.com/article/885226-overview. Accessed: June 30, 3009.
Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005 May. 129(4):534-8. [Medline].
Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009 Jul. 52(7):847-52. [Medline]. [Full Text].
Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009 Apr. 145(1):101-6. [Medline]. [Full Text].
Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014 Mar 27. 123(13):1989-99. [Medline]. [Full Text].